Lap-Chee Tsui — Geneticist Who Found the Cystic Fibrosis Gene, HKU's 14th Vice-Chancellor

This is one of the biographical profiles in "The University of Hong Kong (HKU) Database", covering the University's 14th Vice-Chancellor and geneticist Lap-Chee Tsui. This library's 00–12 reference section (factual) records real names as they are, without credibility badges. For profiles of the University's founders and leadership cohort, see faculty-and-leaders.md; for the contested accounts of presidential governance, see ../13-governance-and-reform/presidents-and-power.md.

---

# 1. Early Life and Education: From "Couldn't Get into an Anglo-Chinese School" to a Pittsburgh PhD

• According to his Wikipedia biography^※ and the Embryo Project entry^※, Tsui was born on 21 December 1950 in Shanghai, with ancestral roots in Hangzhou, Zhejiang; he moved south with his family as a child and grew up in Hong Kong. His parents were Tsui King-leuk and Hui Wai-ching^※.
• According to his geneticist biography^※, he attended Ho Man Tin Government Secondary School for his secondary education, earning A grades in English and Biology in his Form 5 examinations in 1967. He has never been shy about this stretch of his schooling — he once described how he "didn't get into an English-medium secondary school" (升唔到英中) and graduated from university with third-class honours, repeatedly stressing that "interest must come first" (最紧要兴趣行先).
• According to his biography^※, he enrolled in the Biology Department of New Asia College at The Chinese University of Hong Kong (CUHK), earning a BSc with third-class honours in 1972 and an MPhil in 1974; he then went to the United States, obtaining a PhD in biology from the University of Pittsburgh in 1979^※, under the supervision of phage geneticist Roger Hendrix.
• After his doctorate, he first did postdoctoral work at Oak Ridge National Laboratory in the United States^※, then moved in 1981 to the Genetics Department of the Hospital for Sick Children in Toronto, Canada, where he carried out his most important research; he later rose to become the hospital's Chief of Genetics and Head of the Genetics Department, holding concurrent professorships at the University of Toronto and the H.E. Sellers Cystic Fibrosis Research Chair.
• According to the Embryo Project entry, he married Lan Fong Ng and the couple have two sons^※; he holds Canadian citizenship and Hong Kong permanent residency — a status that neatly fits the three-stage arc of his life: "raised in Hong Kong, built a career in North America, returned to run a Hong Kong university."

---

# 2. 1989: How to "Read" an Invisible Gene

This is the summit of Tsui's scientific career, and the key to understanding him. To grasp the weight of this discovery, one must first take in what made it so hard.

The difficulty: an unknown defect, hunted blind. Cystic fibrosis is one of the most common fatal recessive genetic diseases among Western Caucasians, in which the lungs, pancreas and other organs become clogged with abnormally thick secretions. In the 1980s, all anyone knew was that it was genetic — nobody had the faintest idea which gene or which protein was at fault. There was no known defective protein from which one could work backwards to the gene. Tsui and his collaborators took a path that was then brand new: positional cloning — that is, without presupposing the disease molecule, using genetic linkage alone to box in the gene's location on the chromosome step by step. This is widely recognised as the first human disease gene identified purely through linkage analysis and positional cloning^※.

Step one (1985): Pin the disease to chromosome 7. By 1985, Tsui's team had linked the disease gene to DNA markers on chromosome 7^※ — but that was still a broad region containing several million base pairs. It was like knowing the suspect was in a certain city and still having to go door to door.

Step two: Chromosome walking and jumping. Tsui (at the Hospital for Sick Children) collaborated with Francis Collins (then at the University of Michigan, later director of the US National Institutes of Health and leader of the Human Genome Project), combining chromosome walking with the chromosome jumping technique Collins had developed to close in on the target region of chromosome 7, layer by layer. The methodological paper, "Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping," was published in Science in 1989^※.

What exactly do "walking" and "jumping" do? The terms sound abstract, but unpacked they are not hard to grasp. Chromosome walking starts from a known DNA marker and extends, clone by overlapping clone, toward the target region — like crossing a stream stone by stone. It is steady but slow, and it stalls when it hits regions that resist cloning. Chromosome jumping is Collins's "fast-forward": using a specially constructed circularisation library, analysis can "jump" straight over stretches of hundreds of thousands of base pairs from one site to a landing point further on, before returning to walk in fine detail. Together, the two techniques let the team efficiently home in on CFTR within the vast expanse of chromosome 7^※. This approach — "don't worry about what the gene product is; just nail it by position" — was then known as reverse genetics, the mirror image of the traditional "know the protein first, then find the gene" route. CFTR was one of the earliest and most persuasive trophies of this new paradigm.

Step three (1989): Pinpoint the gene and the most common mutation. The paper was accepted in mid-August 1989, and on 8 September three consecutive papers appeared in a single issue of Science, announcing the identification of the CFTR gene^※ — CFTR, the "cystic fibrosis transmembrane conductance regulator," a chloride channel protein. The team also found that about 70% of patients carry the same three-base deletion, the ΔF508 mutation (loss of phenylalanine at position 508)^※. This body of work brought Tsui international fame.

It was not his work alone. The core team also included John R. (Jack) Riordan, Johanna Rommens and Manuel Buchwald at the Hospital for Sick Children, and Francis Collins at the University of Michigan^※. This profile follows the sources in recording Tsui's leadership role; the full authorship as it appears on the papers is a matter for the original literature.

What made it hard was also the "grind." Positional cloning was a race against time and rivals. Tsui has recalled how a competitor "announced" at an academic conference that they had found the gene, leaving him in the audience "sweating with fright" at the thought that years of work were about to be scooped^※; the rival's result later turned out to be wrong. Harder still, he had to persuade his own collaborators that "the other team had not found the disease gene" and to keep going together^※. HKU's honorary degree citation sums up the fineness of the work in one vivid number: in patients, out of roughly 250,000 base pairs, precisely 3 are missing — and it is precisely those 3 missing bases that cause the disease^※. The citation calls it "a major breakthrough in human genetics" and says it "greatly advanced the treatment strategies" for the disease^※.

A carefully choreographed simultaneous announcement. At the time, the discovery was a global science story. The Howard Hughes Medical Institute and the US Cystic Fibrosis Foundation coordinated simultaneous press conferences in Toronto and Washington to amplify the coverage^※; the linkage map from the three Science papers graced that issue's cover^※. One much-told anecdote: Johanna Rommens, a lead author, was hiking in the Rocky Mountains at the time and had to be tracked down by the Royal Canadian Mounted Police (RCMP) to attend the press conference^※ — a measure of the uproar. University of Toronto geneticist Ronald Worton later called it "the greatest achievement"^※ among the hospital's series of disease-gene discoveries. The team's division of labour played to each member's strengths: Batsheva Kerem led the genetic mapping, while Jack Riordan identified the expressed gene using a sweat-gland cDNA library^※. According to the HKU citation, Tsui has published over 300 papers and served on the editorial boards of twenty international journals^※; CFTR is merely the most brilliant of them.

Why this work is repeatedly described as "rule-changing." Before CFTR, finding a disease gene when all one knew was "it's inherited, but we don't know what's wrong" was almost hopeless; this case proved that "you can pull out a gene on chromosome position alone" was feasible. Michigan Medicine's retrospective put it bluntly: the discovery "changed cystic fibrosis care and genetic research forever"^※. Over the next two decades, the causal genes of Huntington's disease, Duchenne muscular dystrophy, polycystic kidney disease and a host of other single-gene disorders were conquered one after another along the same positional-cloning road — the path Tsui and his collaborators first blazed became the standard toolkit of an entire generation of geneticists.

Background note: Tsui's standing as a top geneticist rests on the CFTR discovery; this achievement predates his tenure as HKU Vice-Chancellor and was not carried out at HKU. This library records the institutional affiliation (Hospital for Sick Children / University of Toronto / University of Michigan) as it actually was, so that readers do not mistake it for "HKU research output." His HKU connection lies in his later stewardship of the University and his push for research and internationalisation there.

---

# 3. After CFTR: How One Gene Rewrote the Fate of a Disease

First, how severe the disease was. To gauge the weight of the CFTR discovery, one must know what cystic fibrosis once was. Caused by defective CFTR chloride channels, it makes epithelial tissues of the lungs, pancreas, gut and bile ducts secrete abnormally thick mucus; classic manifestations include elevated chloride in sweat, recurrent bacterial infections and bronchiectatic lung disease, and pancreatic insufficiency^※. In the 1950s, patients' life expectancy was around 5 years; before the 1980s, roughly half of patients did not survive into their twenties^※. This was a disease that killed children — and it was against that backdrop that Tsui's work unfolded.

Finding the gene was only the beginning. The identification of CFTR set off three long-term reverberations for cystic fibrosis, worth a section of their own.

• Diagnosis and genetic counselling. Once the gene was identified, prenatal diagnosis became possible through chorionic villus sampling and amniocentesis, and carrier genetic testing was developed^※. Before this, parents in affected families could only gamble on probability; afterwards, carrier screening and prenatal diagnosis became realities, and many high-risk families could make reproductive decisions with clear molecular information. This kind of genetic testing was the most direct and quickest-to-clinic dividend of knowing the disease gene's sequence.
• From "knowing the gene" to "matching the drug." Identifying CFTR supplied the molecular basis for understanding how mutations disrupt chloride transport and, in turn, organ secretions; the chain of reasoning took over three decades and ultimately produced "CFTR modulator" drugs that act directly on the functional defect of the CFTR protein. The triple combination Trikafta (elexacaftor/tezacaftor/ivacaftor) was approved by the US FDA in October 2019 for patients aged 12 and older carrying at least one ΔF508 mutation^※; eligibility has since been widened repeatedly, and by 2023 it covered children as young as two^※. These drugs can be "matched" only because 1989 revealed which gene — and which protein — was at fault: Tsui's discovery is the wellspring of the entire therapeutic revolution. A disease whose life expectancy was measured in childhood years now lets many patients look forward to near-normal lifespans. Trikafta reaches the vast majority of patients because its three small molecules respectively "correct" and "potentiate" the defective CFTR protein; the list of covered mutations has grown steadily since approval, and by 2023 encompassed more than ninety CFTR mutations and was extended to two-year-olds^※ — every expansion rests on the molecular understanding of "how this mutation breaks, and at which step of the protein," and that understanding traces straight back to the 1989 gene identification.
• A methodological demonstration. Positional cloning thereafter became the standard paradigm for identifying the causal genes of other single-gene disorders — CFTR was the textbook first case. Later review literature flatly calls the discovery "one of the most important triumphs of contemporary human genetics" and cites it as proof that the positional-cloning strategy works^※.

One gene, more than two thousand ways to break. ΔF508 is only the commonest. Over three decades, researchers have found more than two thousand mutation sites in CFTR^※, each disrupting the chloride channel differently — some misfold the protein (like ΔF508), some impair the channel's opening and closing, some prevent the protein from being made at all. That is precisely why CFTR-modulator drugs must be developed mutation-type by mutation-type: the "lock" identified in 1989 turned out to have more than two thousand "wrong keys," each needing a bespoke countermeasure. As to scale, cystic fibrosis affects some 70,000 patients worldwide^※, the majority of European or Caucasian descent — the target Tsui chose back then happens to be one extremely common in the West but rare in East Asia, which is why the Chinese-speaking world has long underestimated the scientific weight of his achievement.

The therapeutic progress in this section belongs to the later development of the CFTR field, not to Tsui's personal output; it is recounted here to show the long-term significance of his 1989 finding, and to keep readers from undervaluing what "one gene mapped" was worth. Cystic fibrosis is far rarer in East Asian populations than in the West — which is precisely why the disease is little known in the Chinese-speaking world even as the CFTR discovery carries enormous scientific weight.

---

# 4. 2002–2014: HKU's 14th Vice-Chancellor

• According to his Wikipedia biography^※ and the HKU succession list^※, Tsui served as HKU's 14th Vice-Chancellor and President from 1 September 2002 to 31 March 2014, succeeding acting Vice-Chancellor Ian Davies and followed by Peter Mathieson — a tenure of about twelve years.
• According to a 2014 SCMP retrospective^※, his term spanned major transformations at HKU, including the centenary (2011), the opening of the Centennial Campus (2012) and the transition to the "3+3+4" four-year undergraduate curriculum (see ../00-overview/history-2.md).

Verifiable milestones of his tenure:

• The Li Ka-shing donation and the renaming of the Medical Faculty (2005). In 2005 the Li Ka Shing Foundation donated HK$1 billion to HKU's Medical Faculty; during Tsui's tenure it was decided to name the faculty the Li Ka Shing (LKS) Faculty of Medicine^※ — one of the largest single donations in HKU's history. The Faculty traces back to the Hong Kong College of Medicine for Chinese, founded in 1887, making it the University's oldest faculty (Sun Yat-sen was a product of the College); naming a faculty of such lineage after a donor stirred discussion among alumni and staff about how to balance naming tradition and philanthropic practice. This profile offers only a neutral record of the facts; the contending accounts of related governance controversies belong to the wild-history section, see ../13-governance-and-reform/; the Faculty's founding lineage is covered separately in faculty-and-leaders.md.
• SARS and the HKU Medical Faculty (2003). During the 2003 SARS outbreak, the HKU Medical Faculty team was the first to isolate the SARS coronavirus, clarify its transmission route and develop a rapid diagnostic test^※. The campaign unfolded within Tsui's tenure; as a geneticist turned Vice-Chancellor, he used it to push HKU further into infectious disease and biomedical research (the Faculty's pandemic-fighting record is covered in faculty-and-leaders.md and ../11-medical-hospital/).
• Centenary and the Centennial Campus (2011–2012). HKU marked its centenary in 2011; in 2012 the Centennial Campus in the western district opened, adding space for the Faculties of Arts, Law and Social Sciences in step with the expansion to the four-year curriculum.
• The "double first-year" curriculum transition. Under the "3+3+4" system, 2012 saw graduates of both the old and the new secondary curricula enter university in the same year — the "double cohort" — forcing every university in Hong Kong to absorb nearly twice its usual intake of first-year students at once; HKU's campus expansion and curriculum reform were designed precisely to accommodate this transition.
• Internationalisation and research orientation. The HKU honorary degree citation lists internationalisation as the main thread of his stewardship, crediting him with raising research standards, safeguarding academic freedom, and overseeing the building of the Centennial Campus^※; he saw "students from different cultural backgrounds debating together" as a core value of the University. Former Council Chairman Leong Che-hung summed up his impression of Tsui as "humble, courteous and principled"^※.
• International rankings and reputation. On 8 November 2007, the UK's Times Higher Education Supplement placed HKU 18th in the world in its "2007 World University Rankings", first among universities in Hong Kong and in the country, and second in Asia (behind only the University of Tokyo)^※; he himself was named "Best University Vice-Chancellor" three times during his twelve years at the helm^※. For ranking methodologies and year-on-year changes, see ../03-rankings/.

Controversial governance events during his tenure (with all parties' accounts set side by side, unadjudicated) fall under the wild-history section and are not developed here; the relevant files are in ../13-governance-and-reform/. This profile records his life, scientific contributions, and verifiable facts of office.

---

# 5. After the Vice-Chancellorship: Founding the Academy of Sciences of Hong Kong, Then Summoned to Plan a New Medical School

Tsui did not retire after leaving HKU; he moved into a "post-presidency" phase holding several posts at once.

• Zhejiang University Qiushi Academy for Advanced Studies (2015). On 9 January 2015 he took up the directorship of the Qiushi Academy for Advanced Studies at Zhejiang University^※, returning to a mainland-China university to foster interdisciplinary research.
• Founding President of the Academy of Sciences of Hong Kong (2015). On 5 December 2015, the Academy of Sciences of Hong Kong was established at Government House, with Tsui as its founding President^※. It is Hong Kong's first scholarly body voluntarily formed by the scientific community itself, using an academy system to bring together leading researchers, with the aims of offering independent professional advice on science policy to the government and promoting science to the public. The founding fellowship numbered 18, drawing together Turing Award laureate Andrew Yao, neuroscientist Nancy Ip, infectious-disease authority Yuen Kwok-yung, chemist Chi-Ming Che and other leading scholars across fields^※; the Academy places no restriction on fellows' nationality, asking only whether they "have contributed to Hong Kong's scientific development," and thereafter elects at most five new fellows every two years^※. After Tsui stepped down, the presidency passed to Dennis Lo, "father of non-invasive prenatal testing." For a geneticist and former Vice-Chancellor to take the lead in founding such an academy was, in a sense, putting into institutional practice his lifelong conviction that "science needs institutional support" — his CFTR work had taught him that any discovery rests on layers of teams, libraries, funding and international coordination; running an academy was simply scaling that same logic from a single laboratory to a whole city.
• President of HUGO (2000–2002). Well before taking the helm at HKU, he served as President of the Human Genome Organisation (HUGO) from 2000 to 2002^※, playing a role in the international coordination of the Human Genome Project — a natural continuation of his positional-cloning background. The Human Genome Project is the mega-project of "sequence first, then go back to find the genes," whereas his CFTR campaign had demonstrated the power of the "map-and-clone" approach on a single disease; the two are of a piece, one micro, one macro, sharing the same methodology. He thus became one of the very few Chinese scientists to have both identified a major disease gene with his own hands and taken charge within an international organisation of the genomic age. It is also worth noting that his key CFTR collaborator Collins went on to lead the US arm of the Human Genome Project and direct the National Institutes of Health — a partnership that, in a sense, kept Tsui connected to the international mainstream of genomics throughout.
• Chairman of the Research Policy Task Force (2017). In 2017 he was appointed chairman of the task force reviewing Hong Kong's research funding policies^※, advising on the local system for allocating research money. For someone who both understands frontier research and has run an entire university, scrutinising "how the money is spent and who gets it" was a remarkably apt fit.
• A "post-presidency" scholar with a stack of hats. More than a decade after stepping down, his public roles have never emptied. According to his official HKU CV, he currently simultaneously holds the posts of President of the Academy of Sciences of Hong Kong, President of King Lun Charity Foundation, Director of Zhejiang University's Qiushi Academy for Advanced Studies, and Emeritus Professor at the University of Toronto^※ — a list spanning Hong Kong, mainland China and Canada. These are no sinecures: the posts correspond respectively to the scientific community's self-organisation (the Academy), philanthropic capital underpinning research (the King Lun Foundation), interdisciplinary institution-building at a mainland university (the Qiushi Academy), and Toronto, the true "home ground" of his academic career — spreading his lifelong conviction that "science needs institutional support" across several tables at once.
• Planning Hong Kong's third medical school (2024–2025). Hong Kong has long had only two medical schools, at HKU and CUHK. With rising demand for healthcare manpower, the government moved to establish a third. In November 2024, the working group on the preparatory work for the new medical school invited interested universities to submit proposals, with a deadline of 17 March 2025 and evaluation expected to be completed within the year^※; on 26 February 2025 the government announced Tsui's appointment as an expert adviser to the working group, drawing on his experience in higher-education leadership and research to help assess the proposals "in a transparent and fair manner" against the established criteria^※. In the end, three universities — HKUST, PolyU and HKBU — submitted proposals before the deadline.
• The outcome: HKUST wins (November 2025). On 18 November 2025, the Executive Council approved the Hong Kong University of Science and Technology (HKUST) as the organiser of Hong Kong's third medical school^※. The working group made its recommendation after assessing the three proposals against ten main criteria^※, covering curriculum design, innovation strategy, teaching and research staff, admissions arrangements, teaching facilities, clinical resources and financial arrangements. Under the plan, HKUST will self-fund HK$2 billion to build a medical school complex at Clear Water Bay, aiming to admit its first cohort of 50 medical students in 2028, offering a four-year second-degree programme; the first cohort is expected to begin internships in 2032; the long-term campus site is in the Northern Metropolis University Education City at Ngau Tam Mei, with interim quarters on the existing Clear Water Bay campus^※, positioning itself as "engineering-medicine integrated and research-oriented"; over the next 25 years, government and HKUST contributions are roughly one-to-one^※. This will be Hong Kong's third medical school — after HKU's and CUHK's — and the first to break the two-school monopoly. The Vice-Chancellor who had once brought a HK$1 billion donation to HKU's Medical Faculty, years later and in the advisory capacity of an expert, took part in the full process of evaluating and selecting a third medical school for the city — while also holding such posts as Chairman of the Council of Chu Hai College, among others.

From "reading" a gene in 1989 to helping select a city's third medical school in 2025, Tsui's role has shuttled ceaselessly between "science" and "institutions": the first half of his life used laboratory methods to solve a specific scientific problem; the second half used the same disposition — "let evidence and standards speak" — to wrestle with the messier public questions of university governance, research policy and medical education.

---

# 6. A Creed for Research and Governance: "Interest First" and "Let Evidence Speak"

What ties together Tsui's research, his university stewardship and his late-career public service is a remarkably consistent set of convictions. This section is drawn from his public interviews and inaugural remarks, all traceable to his own words.

• Interest before glory. A third-class-honours graduate who had not even got into an English-medium secondary school ended up a world-class geneticist — he credits interest and persistence, and repeatedly tells younger generations that "interest must come first"^※.
• Research is a grind. "If you are going to stay the course in research, you must have perseverance, you must persist, and you must be passionate about science. Without passion behind you, you cannot push yourself."^※ When selecting PhD students, what he looks for is precisely whether they can stay up late at the bench and keep going.
• Science and business run on different logics. Having become deeply involved in research policy after stepping down, he holds a clear-eyed view of the value of basic research: "Scientists are people searching for the perfect answer, but business and industry are not like that; for capital, making money is what matters most."^※ He therefore argues that the road "from basic research to products is a long one; everyone should be patient and not too short-sighted"^※, and urges Hong Kong to "push research out" rather than hoarding it as the universities' own trade secret.
• Internationalisation is the main thread of governance. During his presidency, he regarded "students from different cultural backgrounds debating together" as a core value of the University; the HKU honorary degree citation records him as saying: "The more the students come from diverse cultures and backgrounds, the more the discussion will blossom."^※ In an interview after stepping down, he said what he was most proud of — and most reluctant to leave — was "the big family of HKU"^※.

These statements are the mirror image of the methodology behind his positional cloning of CFTR — "don't pre-suppose the answer; let the evidence close in step by step." Whether in the laboratory, the Vice-Chancellor's office or a government working group, he leans on the same approach: "let evidence and standards speak."

---

# 7. The Dual Identity: Why This Library Records Science and Governance Separately

Tsui's case reflects a "dual identity" phenomenon worth attention. In today's research universities, a top scientist becoming Vice-Chancellor is hardly rare — but someone who, like him, first built his reputation on a specific, discipline-rewriting scientific discovery and only then took the helm of a centenarian institution is still unusual. This trajectory breeds a peculiar tension: a scientist used to "letting evidence speak" in the laboratory suddenly faces, in the Vice-Chancellor's chair, the altogether different logics of governance, fundraising, political pressure and public relations. This library's treatment is precisely to keep the two identities separate — the scientific discovery (CFTR) belongs to science, and its excellence is recorded as fact; the governance belongs to governance, and its controversies are placed in the wild-history section, with accounts set side by side and unadjudicated. In this way we neither use his scientific achievements to sidestep governance controversies nor use those controversies to erase his scientific contributions. A person may be an uncontested giant in one domain and enter a field of contested evaluation in another — keeping the two apart is precisely the point of this library's convention of "real names in the factual section, contested accounts set side by side in the wild-history section." Among HKU's successive Vice-Chancellors, Rayson Huang was a chemist, Wang Gungwu a historian, Cheng Yiu-chung a microelectronics engineer and Peter Mathieson a nephrologist — "the scholar as administrator" has been the norm at HKU, and how each man's scholarly background and governance style illuminate each other can be read across in faculty-and-leaders.md.

---

# 8. Honours

According to his Wikipedia biography^※, the geneticist Wikipedia entry^※ and the Canadian Medical Hall of Fame page^※, Tsui holds international science prizes, honours from multiple jurisdictions and fellowships of multiple academies. His honours fall into three bundles: top-tier science prizes recognising the CFTR work, national/regional honours conferred by Canada, France and Hong Kong, and academy fellowships and hall-of-fame inductions from several countries. According to his official HKU CV, he also holds honorary doctorates from fourteen leading universities worldwide^※ — a measure of the transnational reach of his scholarly reputation:

The exact years of the Hong Kong and mainland honours and of the various academy fellowships follow the official registers; this table lists years where verified and leaves "—" where not, without speculation. For the cross-referencing of top-tier fellowship honours with other HKU academicians, see nobel-and-awards.md.

---

# Appendix: Chronology

The table below consolidates the sources of this profile, arranging Tsui's key milestones in chronological order for quick reference. Individual dates follow the official registers; see the corresponding sections above.

---

# Unverified / To Be Checked

• Collaborating team and corresponding authorship of the CFTR discovery: this profile follows institutional histories and biographies in recording his leadership role and principal collaborators (Riordan, Rommens, Buchwald, Collins); the complete author list and corresponding authorship require checking the original literature (the 1989 Science series of three papers).
• Exact years of some honours: Justice of the Peace per the official HKU CV is 2006, Gold Bauhinia Star 2011; the years of the Grand Bauhinia Medal, the Order of Ontario and the various academy fellowships need to be checked against the official registers one by one; this profile leaves them pending verification.
• A detailed list of policy achievements during his presidency: the SCMP retrospective and local reporting provide an overview; itemised data (such as admissions, research funding and year-on-year international ranking movement) require checking HKU's annual reports — see ../03-rankings/ and ../08-finances/.

---

# Related Reading

• Portraits of HKU's successive Vice-Chancellors and academic leaders: faculty-and-leaders.md
• Portraits of notable alumni: notable-alumni.md
• Fellowships and top-tier academic honours: nobel-and-awards.md
• Eileen Chang and HKU in the war generation: eileen-chang-and-stanley-ho-war-generation.md
• File on governance struggles and presidential power: ../13-governance-and-reform/presidents-and-power.md

---